Scisparc宣布,其子公司Neurothera Labs在Sci-210自闭症临床试验中实现了显著的入组增长势头。该进展标志着项目推进的重要里程碑。
Scisparc宣布,其子公司Neurothera Labs在Sci-210自闭症临床试验中实现了显著的入组增长势头。该进展标志着项目推进的重要里程碑。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.